CASC3 and neoplasm: Compared to free BTZ, the non-targeted and PSGL-1-targeted liposomal BTZ formulations resulted in a significant decrease in tumor progression (Supplementary Fig. 5c); statistical analyses of Supplementary Fig. 4 are shown in Supplementary Table 4.